Table 3. Efficacy and relative dose intensity in the test population according to KRAS status determined by ARMS/S.
|
DS WT
|
||
|---|---|---|
| Characteristic | ARMS/S WT (n=38) | ARMS/S MUT (n=9) |
| Partial response | 6 | 0 |
| Stable disease | 19 | 5 |
| Progressive disease | 13 | 4 |
| Response rate | 16.0%a | 0%a |
| Disease control rate | 66.0% | 56.0% |
| Progression-free survival, median (months) | 5.0 | 1.7 |
| Overall survival, median (months) | 12.1 | 3.8 |
| Relative dose intensity | ||
| Cetuximab, median (range) | 0.94 (0.57–1.00) | 0.93 (0.57–1.00) |
Abbreviations: ARMS/S=amplification refractory mutation system–Scorpion assay; DS=direct sequencing; MUT=mutant; WT=wild type.
a
P=0.257 (one-tailed Fisher's exact test).